key: cord-0770576-uebgsdhy
authors: Lacwik, Piotr; Szydłowska, Dorota; Kupczyk, Maciej; Pałczyński, Cezary; Kuna, Piotr
title: High levels of anxiety during the COVID-19 pandemic as a risk factor of clinical worsening in patients with severe asthma
date: 2021-01-10
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2020.12.060
sha: 5d46915e19fc4ae2a455b9efcac9078a2bfb1303
doc_id: 770576
cord_uid: uebgsdhy

nan

The authors declare that they have no known competing financial interests or 36 personal relationships that could have appeared to influence the work reported in this 37 paper. has severely affected both physical and psychological health of people all around the world 3 . Since 55 the first reports of severe respiratory syndrome coronavirus 2 (SARS-CoV-2), it has proven to be 56 highly contagious and potentially dangerous. From the beginning it was considered especially 57 threatening to vulnerable populations, such as patients with chronic respiratory conditions, which 58 could naturally lead to increased levels of stress and anxiety. The aim of our study was to assess the 59 levels of anxiety and its impact on disease control and quality of life in patients with severe asthma, 60 treated in our tertiary allergology center in the early months of COVID-19 pandemic. 61

We surveyed all of the severe asthma patients undergoing biological treatment with omalizumab, 62 mepolizumab and benralizumab in the National Severe Asthma treatment Program during their visits 63 in March/June 2020. Our aim was to assess the patients on their first visit after the COVID-19 64 pandemic declaration by the World Health Organization. We asked each patient to complete The 65

State-Trait Anxiety Inventory (STAI), which is a validated tool for measuring anxiety in adults, both as 66 a temporary condition (state) and a general, long-standing personal quality (trait) 5 . All patients 67 (Tables 1 and 2) . 86

The high state anxiety group included a higher proportion of patients with both significant ACQ 87 increase (53.3% vs 10.5%) and mAQLQ decrease (30.0% vs 15.8%) compared to those with low to 88 moderate state anxiety (Table 1) . A similar tendency could be observed in asthmatics with high trait 89 anxiety (57.1% vs 21.5% for significant ACQ increase and 28.6% vs 20.3% for mAQLQ decrease) 90 compared to the rest of the group (Table 2) . 91

Linear regression analysis showed that both state and trait anxiety were significantly associated with 92 the change in ACQ (p<0.001 and p<0.01, respectively), but not the mAQLQ scores. The mean change 93 in ACQ was -0.24, -0.18 and +0.98 for patients with low, moderate and high level of state anxiety, 94 respectively (Table 1) . Logistic regression results suggested that a high level of state anxiety may 95 prove to be a risk factor of significant decline (exceeding the MCID) in ACQ (OR= 9.71, p<0.001) and 96 J o u r n a l P r e -p r o o f mAQLQ (OR=2.29, p=0.008) compared to low/moderate state anxiety group. Regression analyses 97 were adjusted for age, gender and treatment length. 98

Anxiety and mental comorbidities are commonly associated with poor asthma control, but to date 99 few studies approached this subject in clinical setting, most commonly in adolescents 7-9 . Our 100 observations showed that a major event, like the rise of a global pandemic, may significantly affect 101 patients' level of anxiety, which can reflect on their quality of life and disease control. In previously 102 published studies, the outbreak of SARS-COV2 has been shown to cause a spectrum of mental health 103 issues, including anxiety 10 . Our analyses confirmed that high levels of anxiety are associated with 104 worse asthma control in the population of severe asthmatics and may be a risk factor for significant 105 worsening of disease control and asthma-related quality of life. 106

We believe the major strengths of our analysis were the use of a specialized anxiety-oriented scale 107 and the study group, as severe asthmatics are rarely the subject of trials focusing on anxiety in 108 asthma, while being potentially the most vulnerable group, in whom anxiety and stress can have 109 clinically significant consequences. Moreover, the timing of assessments was advantageous, as all 110 patients were evaluated soon after the announcement of global pandemic, which universally 111 affected the whole world with high potential for causing stress and anxiety in vulnerable patients 112 with chronic diseases. One major limitation of our study is the lack of measure of anxiety before 113 COVID-19 was declared a pandemic. Moreover, worsening of asthma caused by other COVID-related 114 factors, like increased levels of stress and depression, or greater exposure to household allergens as 115 a result of widespread shutdown, could affect the changes in ACQ and AQLQ scores. As a result, it is 116 impossible to rule out that the increased levels of anxiety were actually caused by loss of asthma 117 control unrelated to our patients' emotional state. However, the study group comprised long-118 observed patients with stable disease on biological treatment. Moreover, the majority of patients 119 reported in the 'COVID-19 survey', that the changes brought on by the pandemic affected their 120 perceived psychological well-being. 121

Our results show that high levels of anxiety may be a risk factor of clinical worsening in patients with 122 severe asthma. A regular screening of severe asthmatics using STAI questionnaire could be a valuable 123 addition in asthmatic patient care, with further studies required to assess whether an intervention 124 aimed at reducing anxiety could prove effective in improving asthma control. 125 

Anxiety and depression may associate with poorer control and 131 quality of life in adults with asthma

Anxiety Contributes to Poorer Asthma Outcomes

Inner-City Black Adolescents

COVID-19 pandemic and mental health consequences: Systematic 135 review of the current evidence

Measures of anxiety: State-Trait Anxiety Inventory (STAI), Beck Anxiety Inventory 137 (BAI), and Hospital Anxiety and Depression Scale-Anxiety (HADS-A)

Determining a minimal important change in a 140 disease-specific Quality of Life Questionnaire

Association between asthma symptom scores and 142 perceived stress and trait anxiety in adolescents with asthma

Anxiety/depression changes are associated with 145 improved asthma control perception in asthmatic adolescents after adequate management

Anxiety, Depression, and Asthma 148 Control: Changes After Standardized Treatment

The outbreak of COVID-19

coronavirus and its impact on global mental health

Age (years), mean (SD)

Control Questionnaire; mAQLQ-mini Asthma Quality of Life Questionnaire 164

The ACQ ranges for controlled

Changes exceeding the minimal clinically important difference of 0.5 points were considered 167 significant in both mAQLQ decline and ACQ increase

The authors thank the nursing staff from the Department of Internal Medicine, Asthma and Allergy, 127 for their assistance in recruiting patients for this study. 128 129 J o u r n a l P r e -p r o o f